Skip to content

Sophie Kitzmüller, PhD

Study Coordinator

Research Statement

It is important to me that patients who agree to take part in a clinical trial at the EB House feel well cared for, that all team members are best prepaired and that any issues that arise can be resolved quickly. Good communication with participating departments and international cooperation partners and accurate data management are crucial.

Curriculum Vitae Sophie Kitzmüller

Professional career

Since 2019
Head of the EB Academy

Since 2016
Project- and Study Coordination at the EB House Austria

PhD student at the department for Molecular Biology at the Paris Lodron University Salzburg

Scientific Associate at the EB House Austria


Academic career

PhD, Paris Lodron University Salzburg

MSc in Genetics and Biotechnology, Paris Lodron University Salzburg

BSc in Genetics and Molecular Biology, Paris Lodron University Salzburg


Awards and Fellowships

OEGMBT Poster Price, 7th Annual Meeting of the OEGMBT, 2015


Additional qualifications/training

Steady updates on GCP guidelines, latest certificate from JSB, 2018
Certified Data Protection Officer, TÜV, 2017
Training: IATA guidelines, GSSA, 2016 Training: Data protection and confidentiality, SALK, 2016
Training: Project management, Paris Lodron University Salzburg, 2015
Training: Health monitoring for lab animals, Charles River, 2015
FELASA certificate, tiz-bifo Akademy, 2013
FACS training, Beckman Coulter, 2012
FACS training, eBioscience, 2011

Original articles

  1. Kiritsi D, Dieter K, Niebergall-Roth E, Fluhr S, Daniele C, Esterlechner J, Sadeghi S, Ballikaya S, Erdinger L, Schauer F, Gewert S, Laimer M, Bauer JW, Hovnanian A, Zambruno G, El Hachem M, Bourrat E, Papanikolaou M, Petrof G, Kitzmüller S, Ebens CL, Frank MH, Frank NY, Ganss C, Martinez AE, McGrath JA, Tolar J, Kluth MA. Clinical trial of ABCB5-positive mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI insight 2021.
  2. Pinheiro DF, Szenes-Nagy AB, Maurano MM, Lietzenmayer M, Klicznik MM, Holly R, Kirchmeier D, Kitzmueller S, Achatz-Straussberger G, Rosenblum MD, Thalhamer J, Abbas AK, Gratz IK. Cutting Edge: Tissue Antigen Expression Levels Fine-Tune T Cell Differentiation Decisions In Vivo. Journal of immunology (Baltimore, Md : 1950) 2020.
  3. Prodinger C, Diem A, Ude-Schoder K, Piñón-Hofbauer J, Kitzmueller S, Bauer JW, Laimer M. Profiling trial burden and patients’ attitudes to improve clinical research in epidermolysis bullosa. Orphanet Journal of Rare Diseases 2020;15:182
  4. Peking P, Breitenbach JS, Ablinger M, Muss WH, Poetschke FJ, Kocher T, Koller U, Hainzl S, Kitzmueller S, Bauer JW, Reichelt J, Lettner T, Wally V. An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex. Br J Dermatol. 2019;180(1):141-148.
  5. Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, Ablinger M, Felder TK, Hofbauer P, Wolkersdorfer M, Lagler FB, Hitzl W, Laimer M, Kitzmuller S, Diem A, Bauer JW. Diacerein Orphan Drug Development for Epidermolysis Bullosa Simplex: A Phase 2/3 Randomized, Placebo-Controlled, Double-Blind Clinical Trial. J Am Acad Dermatol 2018.
  6. Peking P, Koller U, Hainzl S, Kitzmueller S, Kocher T, Mayr E, Nystrom A, Lener T, Reichelt J, Bauer JW, Murauer EM. A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair. Mol Ther Nucleic Acids 2016;5:e287.
  7. Wally V, Kitzmueller S, Lagler F, Moder A, Hitzl W, Wolkersdorfer M, Hofbauer P, Felder TK, Dornauer M, Diem A, Eiler N, Bauer JW. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study. Orphanet J Rare Dis 2013;8:69.
  8. Bach D, Weiss R, Hessenberger M, Kitzmüller S, Weinberger E, Krautgartner WD, Hauser-Kronberger C, Boehler C, Thalhamer J, Scheiblhofer S. Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice. Allergy 2012; 67(11):1365-74
  9. Weiss R, Hessenberger M, Kitzmüller S, Bach D, Weinberger E, Krautgartner D, Hauser-Kronberger C, Malissen B, Boehler C, Kaliaf YN, Thalhamer J, Scheiblhofer S. Transcutaneous vaccination via laser microporation. J Contr Release 2012; 162(2):391-9


  1. Wally V, Reisenberger M, Kitzmüller S, Laimer M. Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosa. Orphanet Journal of Rare Diseases 2020;15:292.
  2. Scharfenberger L, Hennerici T, Király G, Kitzmüller S, Vernooij M, Zielinski JG. Transgenic mouse technology in skin biology: generation of complete or tissue-specific knockout mice. J Inv Dermatol 2014, 134(1):e16
Back to main navigation